Eye-care specialist, Akorn Inc, has agreed to buy Hi-Tech Pharmacal Co. for $640 million in cash. This will allow Akorn to expand into areas including cold and cough treatments.

In a decision that resonates with many critics of mootness fees, a U.S. district judge for the Northern District of Illinois ordered counsel for Akorn Inc. shareholders to return $332,500 in ...